Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.

Eskelund CW, Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Pedersen LB, Geisler CH, Jerkeman M, Grønbæk K

DOI: 10.3324/haematol.2018.194399
Published: 2018 Nov
Container: Haematologica
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2018.194399,
  title = {Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.},
  author = {Eskelund CW and Albertsson-Lindblad A and Kolstad A and Laurell A and Räty R and Pedersen LB and Geisler CH and Jerkeman M and Grønbæk K},
  year = {2018},
  journal = {Haematologica},
  doi = {10.3324/haematol.2018.194399},
  url = {https://doi.org/10.3324/haematol.2018.194399}
}

RIS

TY  - JOUR
TI  - Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.
AU  - Eskelund CW
AU  - Albertsson-Lindblad A
AU  - Kolstad A
AU  - Laurell A
AU  - Räty R
AU  - Pedersen LB
AU  - Geisler CH
AU  - Jerkeman M
AU  - Grønbæk K
PY  - 2018
JO  - Haematologica
DO  - 10.3324/haematol.2018.194399
UR  - https://doi.org/10.3324/haematol.2018.194399
ER  -

APA

CW, E., A, A., A, K., A, L., R, R., LB, P., CH, G., M, J., & K, G. (2018). Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.. Haematologica. https://doi.org/10.3324/haematol.2018.194399

Source records

pubmed · retrieved 2026-09-26T22:12:00.054Z